GU Cancers Symposium 2011: ASCO ASTRO SUO - Role of traditional and modern hormone therapy for biochemical failures after local therapy - Session Highlights

ORLANDO, FL USA (UroToday.com) - PSADT helps to stratify risk of death from recurrent CaP after surgery; <3 months results in 100% mortality. D’Amico showed that this is also important for post-RT patients. ADT improves freedom from disease recurrence in men with a fast PSADT, but less so for a slow (>12 months) PSADT. He then discussed intermittent androgen deprivation therapy. The goals are to prolong time to castration-resistance and lessen toxicity. The SWOG data on this is pending. Other approaches are to use bicalutamide monotherapy, but two underpowered studies did not show benefit. An anti-androgen plus 5-ARI study in older patients is ongoing. Regarding new therapies, the amplified androgen receptor is targeted by abiraterone. However, are they useful in earlier, non-amplified AR disease? Neo-adjuvant pre-surgery use of abiraterone is being studied, but some of the first patients had an excellent response, including P0. Using combinations of androgen-targeted drugs holds great promise going forward, Dr. Small concluded.

Presented by Eric J. Small, MD at the 2011 Genitourinary Cancers Symposium, General Session II: Prostate Cancer Therapy for Recurrent Disease - February 17-19, 2011 - Orlando World Center Marriott, Orlando, Florida USA


The opinions expressed in this article are those of the UroToday.com Contributing Medical Editor and do not necessarily reflect the viewpoints of the GU Cancers Symposium, ASCO, ASTRO, or SUO




email news signup